Nerlynx (neratinib tablets - Puma) — Cigna
Breast Cancer – Recurrent or Metastatic HER2-Positive Disease
Initial criteria
- Patient age ≥ 18 years AND
- Patient has HER2-positive breast cancer AND
- EITHER (the medication is used in combination with capecitabine AND patient has tried at least two prior anti-HER2 based regimens) OR (the medication is used in combination with one of the following: capecitabine, paclitaxel, or Kadcyla (ado-trastuzumab emtansine intravenous infusion) AND patient has brain metastases)
Approval duration
1 year